Clinical Trial Update: Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]

View source ↗

Summary

A specified drug-use survey trial is evaluating Vedolizumab 300 mg given by IV infusion for Crohn's disease. The study is sponsored by Takeda and is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Vedolizumab (Entyvio) (Vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Crohn's Disease | Status: ACTIVE_NOT_RECRUITING